Please use a PC Browser to access Register-Tadawul
Get It
6 Analysts Have This To Say About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. +1.00% Pre
Ionis Pharmaceuticals, Inc. IONS | 81.96 81.96 | +1.00% 0.00% Pre |
Ionis Pharmaceuticals (NASDAQ:IONS) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Ionis Pharmaceuticals, presenting an average target of $97.0, a high estimate of $103.00, and a low estimate of $87.00. Surpassing the previous average price target of $83.67, the current average has increased by 15.93%.
Decoding Analyst Ratings: A Detailed Look
The analysis of recent analyst actions sheds light on the perception of Ionis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Stringer | Needham | Raises | Buy | $103.00 | $90.00 |
| Allison Bratzel | Piper Sandler | Raises | Overweight | $87.00 | $77.00 |
| Yanan Zhu | Wells Fargo | Raises | Overweight | $100.00 | $82.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $95.00 | $82.00 |
| Mani Foroohar | Leerink Partners | Raises | Outperform | $100.00 | $85.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $97.00 | $86.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ionis Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Ionis Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.
For valuable insights into Ionis Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Ionis Pharmaceuticals analyst ratings.
Unveiling the Story Behind Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Ionis Pharmaceuticals: Delving into Financials
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Ionis Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 17.12% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Ionis Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -82.06%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -20.58%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.27%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 2.41. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Significance of Analyst Ratings Explained
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
